Anti k8.1 sc 65446

Manufactured by Santa Cruz Biotechnology

Anti-K8.1 (sc-65446) is a primary antibody product offered by Santa Cruz Biotechnology. It is designed for the detection of K8.1 protein expression in various biological samples. The core function of this antibody is to specifically bind to and detect the K8.1 protein target.

Automatically generated - may contain errors

Lab products found in correlation

Anti tubulin gtu 88, by Merck Group (2 mentions) Recombinant human ifn β, by Thermo Fisher Scientific (1 mentions) Anti cbp sc 369, by Santa Cruz Biotechnology (1 mentions) Doxycycline dox, by Merck Group (1 mentions) Anti flag, by Merck Group (1 mentions) Anti irf3, by Santa Cruz Biotechnology (1 mentions) Anti β actin a5441, by Merck Group (1 mentions) Anti fbw7 a301 720a, by Fortis Life Sciences (1 mentions) Anti flag f1804, by Merck Group (1 mentions) Anti cox 4 4850, by Cell Signaling Technology (1 mentions) Cycloheximide (chx), by Merck Group (1 mentions) Etoposide, by Merck Group (1 mentions)

2 protocols using anti k8.1 sc 65446

Inhibition of KSHV Replication

Check if the same lab product or an alternative is used in the 5 most similar protocols

Doxycycline (Dox), sodium butyrate (NaB), and phosphonoacetic acid (PAA)
were purchased from Sigma. PAA was used at 100 μM to inhibit KSHV
replication. Recombinant human IFNβ was from Peprotech (300–02BC).
The following antibodies were used in our study: anti-FLAG (F1804, Sigma),
anti-tubulin (GTU-88, Sigma), anti-LANA (13–210-100, Advanced
Biotechnologies), anti-ORF45 (sc-53883, Santa Cruz), anti-K8 (sc-57889, Santa
Cruz), anti-K8.1 (sc-65446, Santa Cruz), anti-ORF26 (NBP1–47357, Novus
Biologicals), anti-vIRF3 (NB200–167, Novus Biologicals), anti-CBP
(sc-369, Santa Cruz), anti-IRF3 (sc-33641, Santa Cruz), and anti-pIRF3 (S396)
(4947S, Cell Signaling). Anti-RTA and anti-ORF6 antibodies were generously
provided by Dr. Yoshihiro Izumiya (University of California, Davis) and Dr. Gary
Hayward (Johns Hopkins University), respectively.

Golas G.J., Jang S.J., Naik N.G., Alonso J.D., Papp B, & Toth Z. (2019). Comparative analysis of the viral interferon regulatory factors of KSHV for their requisite for virus production and inhibition of the type I interferon pathway. Virology, 541, 160-173.

+ Open protocol

+ Expand

Antibody Validation for KSHV Research

Check if the same lab product or an alternative is used in the 5 most similar protocols

Chemicals were purchased from the following manufacturers: cycloheximide (CHX), doxycycline (Doxy), sodium butyrate (NaB), MG132, and etoposide were obtained from Sigma; A-1210477 was obtained from Cayman Chemical; and AT-101 was procured from Apex Bio. Primary antibodies were purchased from the following manufacturers: anti-MCL-1 (4572), anti-ubiquitin (3933), anti-mTOR (7959), and anti-KSHV LANA (LNA-1; 4013) were purchased from Abcam; anti-FBW7 (A301-720A) was obtained from Bethyl; anti-MCL-1 (sc-12756), anti-GST (sc-138), anti-Lamin A/C (sc-625), anti-ORF45 (sc-53883), and anti-K8.1 (sc-65446) were obtained from Santa Cruz; anti-β-actin (A-5441), anti-FLAG (F1804), and anti-tubulin (GTU-88) were purchased from Sigma; anti-V5 (MA5-15253) was obtained from Invitrogen; anti-Au (901901) was purchased from BioLegend; anti-HA (M180-3) was procured from MBL; anti-Cyclin E (2983) and anti-COXIV (4850) were purchased from cell signaling technology; anti-K2 (13-214-050) was obtained from ABI. Myc antibody was kindly provided by Dr. Jin-Hyun Ahn (Sungkyunkwan University). Anti-RTA and anti-ORF6 antibodies were generously provided by Dr. Yoshihiro Izumiya (University of California, Davis) and Dr. Gary Hayward (Johns Hopkins University), respectively.

Kim Y.J., Kim Y., Kumar A., Kim C.W., Toth Z., Cho N.H, & Lee H.R. (2021). Kaposi’s sarcoma-associated herpesvirus latency-associated nuclear antigen dysregulates expression of MCL-1 by targeting FBW7. PLoS Pathogens, 17(1), e1009179.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!